ReviewAmerican journal of Alzheimer's disease and other dementias
Cholesterol and apolipoprotein E in Alzheimer's disease.
Review in American journal of Alzheimer's disease and other dementias. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The efficacy of statins in the treatment of Alzheimer's disease: a meta-analysis of randomized controlled trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Pooled it
- Target the Heart: A New Axis of Alzheimer's Disease Prevention.Journal of dementia and alzheimer's disease · 2025Article
- Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis.PLoS medicine · 2014Article
- Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice.Molecular neurobiology · 2012Article
- Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2012Article
- Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation.Human molecular genetics · 2011Article
- Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease.Neurochemical research · 2010Article
- Effects of cholesterol and its 24S-OH and 25-OH oxysterols on choline acetyltransferase-positive neurons in brain slices.Pharmacology · 2010Article
- Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering.Expert opinion on drug metabolism & toxicology · 2008Review
- Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders.British journal of pharmacology · 2008Review
- Statins and dementia.Current atherosclerosis reports · 2007Review
- Cholesterol level, statin use and Alzheimer's disease in adults with Down syndrome.Neuroscience letters · 2007Article
- The presence of neurological soft signs along the psychosis proneness continuum.Schizophrenia bulletin · 2006Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in North America and Europe. The incidence of the disease rises dramatically with age. AD is a complex multifactorial disorder that involves numerous susceptibility genes, but the exact pathogenesis and biochemical basis of AD is not well understood Cholesterol is receiving a great deal of attention as a potentially crucial factor in the etiology of AD. Almost all cholesterol in the brain is synthesized in the brain. Cholesterol exits the brain through the blood-brain barrier (BBB) in the form of apolipoprotein E (ApoE) or by first being converted to a more polar compound, 24(S)-hydroxycholesterol, which is elevated in individuals with AD. The key event leading to AD appears to be the formation and aggregation in the brain of amyloid beta (Abeta) peptide, a proteolytically derived product of amyloid precursor protein (APP). Cholesterol has been demonstrated to modulate processing of APP to Abeta. High levels of cholesterol are associated with increased risk of AD. Patients taking cholesterol-lowering statins have a lower prevalence of AD. ApoE, which transports cholesterol throughout the brain, exhibits an isoform-specific association with AD such that the E4 isoform, by unknown mechanisms, shifts the onset curve toward an earlier age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.